Affymetrix, Inc. (NASDAQ:AFFX) today announced the availability of the most widely cited gene expression microarray for use on the GeneAtlas ® Personal Microarray System, bringing the power of the world’s largest collection of referenced microarray gene expression data to the personal bench-top of every life scientist. The new array strip format for the GeneChip ® Human Genome (HG)-U133 Array combined with the easy workflow of the GeneAtlas System gives researchers a cost-effective solution for in-house whole-genome expression analysis.
Proven performance from the industry standard The Affymetrix(R) Human Genome U133+ PM Array Strip en ...

Proven performance from the industry standard The Affymetrix(R) Human Genome U133+ PM Array Strip enables expression profiling of four samples at a time using the same content as the GeneChip(R) HT HG-U133+ PM Array Plate, which is based on the industry-standard GeneChip(R) Human Genome U133 Plus 2.0 Array.* (Photo: Business Wire)

The new HG-U133+ PM Array Strip leverages the knowledge accumulated from multiple sources, including UniGene, RefSeq, the National Center for Biotechnology information (NCBI), and GenBank ® to provide the most comprehensive view of the transcribed genome. Using more than 500,000 probes for independent measurements of gene expression per sample and as many as 9 to 11 unique probes to interrogate every mRNA transcript, the HG-U133+ PM Array Strip delivers a high level of sequence coverage and data confidence.

Additionally, the GeneAtlas System’s data analysis solution automatically translates the new array strip’s differential expression data into relevant results. It also mines through thousands of research papers that reference the HG-U133 Array design for findings that are significant to a gene or gene-network of interest. Moreover, since Affymetrix routinely updates sequence files every six months for all of its arrays, researchers are assured access to the most relevant whole-genome information and the highest sequence coverage available.

“By designing the most widely cited array for use on the industry’s first personal microarray analysis system, we are unlocking important content for a whole new set of scientists who couldn’t access it before,” said Kevin Cannon, PhD, Vice President of Marketing for Expression Applications at Affymetrix. “The power of the HG-U133 Array on the GeneAtlas System unleashes a tremendous opportunity for discovery,” Dr. Cannon added. “Affymetrix is enabling life scientists, at every level and in all areas, to publish more quickly because of the superior performance, high data confidence, and easy workflow solution that we’re delivering.”

Other array strips available for use on the complete personal GeneAtlas System for microarray processing include the Affymetrix ® Human Genome U219 Array Strip as well as the Affymetrix ® MG-430 PM Array Strip and Affymetrix ® RG-230 PM Array Strip, for mouse and rat, respectively; and the Affymetrix ® Human Gene 1.1 ST Array Strip, Affymetrix ® Mouse Gene 1.1 ST Array Strip, and Affymetrix ® Rat Gene 1.1 ST Array Strip for gene, exon, and alternative splicing analysis.

Learn more about the power of the new HG-U133+ PM Array Strip on the GeneAtlas Personal Microarray System.

About Affymetrix

Affymetrix technology is used by the world's top pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes. More than 2,100 systems have been shipped around the world and more than 23,500 peer-reviewed papers have been published using the technology. Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Santa Clara, Cleveland, Ohio, and Singapore. The company has about 900 employees worldwide and maintains sales and distribution operations across Europe, Latin America, and Asia. For more information about Affymetrix, please visit http://www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2010, and other SEC reports for subsequent quarterly periods.

NOTE: Affymetrix, the Affymetrix logo, GeneChip, and GeneAtlas, are trademarks or registered trademarks of Affymetrix, Inc.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6758938&lang=en

Copyright Business Wire 2010